Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN(®) REVEAL Trial.

Mol Cell Biochem · 2014 · PMC4176569 · PMID 25185754

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Other secondary endpoints such as apo-A, apo-B, hs-CRP, BMI, and blood pressure, did not reach statistical significance, irrespective of the Cohorts and may require longer treatment regiment to claim differences.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.